<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28575585</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2164-554X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Human vaccines &amp; immunotherapeutics</Title>
          <ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transforming growth factor-β: A therapeutic target for cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1741</StartPage>
          <EndPage>1750</EndPage>
          <MedlinePgn>1741-1750</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2017.1327107</ELocationID>
        <Abstract>
          <AbstractText>Transforming growth factor-β (TGF-β) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-β plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-β and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-β pathway have been identified. This review focuses on identifying the mechanisms through which TGF-β is involved in tumorigenesis and current therapeutics that are under development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Haque</LastName>
            <ForeName>Sulsal</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , University of Cincinnati , Cincinnati , OH , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morris</LastName>
            <ForeName>John C</ForeName>
            <Initials>JC</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Internal Medicine , University of Cincinnati , Cincinnati , OH , USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>b University of Cincinnati Cancer Institute , Cincinnati , OH , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>06</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Hum Vaccin Immunother</MedlineTA>
        <NlmUniqueID>101572652</NlmUniqueID>
        <ISSNLinking>2164-5515</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016376">Oligonucleotides, Antisense</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009389" MajorTopicYN="N">Neovascularization, Pathologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016376" MajorTopicYN="N">Oligonucleotides, Antisense</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antisense oligonucleotide</Keyword>
        <Keyword MajorTopicYN="Y">cancer</Keyword>
        <Keyword MajorTopicYN="Y">epithelial-mesenchymal transition</Keyword>
        <Keyword MajorTopicYN="Y">monoclonal antibody</Keyword>
        <Keyword MajorTopicYN="Y">transforming growth factor-β</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28575585</ArticleId>
        <ArticleId IdType="pmc">PMC5557219</ArticleId>
        <ArticleId IdType="doi">10.1080/21645515.2017.1327107</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Derynck R, Akhurst RJ, Balmain A. 
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet
2001; 29(2):117-29; PMID:11586292; https://doi.org/10.1038/ng1001-117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1001-117</ArticleId>
            <ArticleId IdType="pubmed">11586292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumont N, Arteaga CL. 
Targeting the TGF beta signaling network in human neoplasia. Cancer Cell
2003; 3(6):531-6; PMID:12842082; https://doi.org/10.1016/S1535-6108(03)00135-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00135-1</ArticleId>
            <ArticleId IdType="pubmed">12842082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J.
TGF-beta signal transduction. Annu Rev Biochem
1998; 67: 753-91; PMID:9759503; https://doi.org/10.1146/annurev.biochem.67.1.753</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.67.1.753</ArticleId>
            <ArticleId IdType="pubmed">9759503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojtowicz-Praga S.
Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs
2003; 21(1):21-32; PMID:12795527; https://doi.org/10.1023/A:1022951824806</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1022951824806</ArticleId>
            <ArticleId IdType="pubmed">12795527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Casillas F, Wrana JL, Massague J. 
Betaglycan presents ligand to the TGF beta signaling receptor. Cell
1993; 73(7):1435-44; PMID:8391934; https://doi.org/10.1016/0092-8674(93)90368-Z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(93)90368-Z</ArticleId>
            <ArticleId IdType="pubmed">8391934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sankar S, Mahooti-Brooks N, Centrella M, McCarthy TL, Madri JA. 
Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J Biol Chem
1995; 270(22):13567-72; PMID:7768960; https://doi.org/10.1074/jbc.270.22.13567</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.270.22.13567</ArticleId>
            <ArticleId IdType="pubmed">7768960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savage C, Das P, Finelli AL, et al.. 
Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci U S A
1996; 93(2):790-4; PMID:8570636; https://doi.org/10.1073/pnas.93.2.790</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.93.2.790</ArticleId>
            <ArticleId IdType="pmc">PMC40134</ArticleId>
            <ArticleId IdType="pubmed">8570636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dou C, Lee J, Liu B, Liu F, Massague J, Xuan S, Lai E. 
BF-1 interferes with transforming growth factor beta signaling by associating with Smad partners. Mol Cell Biol
2000; 20(17):6201-11; PMID:10938097; https://doi.org/10.1128/MCB.20.17.6201-6211.2000</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.20.17.6201-6211.2000</ArticleId>
            <ArticleId IdType="pmc">PMC86095</ArticleId>
            <ArticleId IdType="pubmed">10938097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. 
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development
1995; 121(6):1845-54; PMID:7600998</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7600998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. 
TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development
1997; 124(13):2659-70; PMID:9217007</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3850286</ArticleId>
            <ArticleId IdType="pubmed">9217007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, Ding J, Ferguson MW, Doetschman T. 
Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet
1995; 11(4):409-14; PMID:7493021; https://doi.org/10.1038/ng1295-409</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1295-409</ArticleId>
            <ArticleId IdType="pmc">PMC3855390</ArticleId>
            <ArticleId IdType="pubmed">7493021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. 
p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci
2002; 115(Pt 15):3193-206; PMID:12118074</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12118074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. 
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem
2000; 275(47):36803-10; PMID:10969078; https://doi.org/10.1074/jbc.M005912200</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M005912200</ArticleId>
            <ArticleId IdType="pubmed">10969078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, Hebert MC, Zhang YE. 
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J
2002; 21(14):3749-59; PMID:12110587; https://doi.org/10.1093/emboj/cdf366</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/cdf366</ArticleId>
            <ArticleId IdType="pmc">PMC126112</ArticleId>
            <ArticleId IdType="pubmed">12110587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, et al.. 
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science
1996; 271(5247):350-3; PMID:8553070; https://doi.org/10.1126/science.271.5247.350</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.271.5247.350</ArticleId>
            <ArticleId IdType="pubmed">8553070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S. 
Frequency of Smad gene mutations in human cancers. Cancer Res
1997; 57(13):2578-80; PMID:9205057</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halder SK, Beauchamp RD, Datta PK. 
Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res
2005; 307(1):231-46; PMID:15922743; https://doi.org/10.1016/j.yexcr.2005.03.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2005.03.009</ArticleId>
            <ArticleId IdType="pubmed">15922743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. 
Smad6 inhibits signalling by the TGF-beta superfamily. Nature
1997; 389(6651):622-6; PMID:9335505; https://doi.org/10.1038/39355</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/39355</ArticleId>
            <ArticleId IdType="pubmed">9335505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al.. 
Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature
1997; 389(6651):631-5; PMID:9335507; https://doi.org/10.1038/39369</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/39369</ArticleId>
            <ArticleId IdType="pubmed">9335507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alevizopoulos K, Vlach J, Hennecke S, Amati B. 
Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J
1997; 16(17):5322-33; PMID:9311992; https://doi.org/10.1093/emboj/16.17.5322</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/16.17.5322</ArticleId>
            <ArticleId IdType="pmc">PMC1170164</ArticleId>
            <ArticleId IdType="pubmed">9311992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. 
Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature
2000; 407(6804):592-8; PMID:11034201; https://doi.org/10.1038/35036504</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35036504</ArticleId>
            <ArticleId IdType="pubmed">11034201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. 
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol
2001; 3(4):400-8; PMID:11283614; https://doi.org/10.1038/35070086</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/35070086</ArticleId>
            <ArticleId IdType="pubmed">11283614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, Eilers M, Leon J, Larsson LG. 
Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene
2003; 22(3):351-60; PMID:12545156; https://doi.org/10.1038/sj.onc.1206145</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1206145</ArticleId>
            <ArticleId IdType="pubmed">12545156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. 
Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell
2001; 12(1):27-36; PMID:11160820; https://doi.org/10.1091/mbc.12.1.27</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.12.1.27</ArticleId>
            <ArticleId IdType="pmc">PMC30565</ArticleId>
            <ArticleId IdType="pubmed">11160820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu PP, Shen X, Huang D, Liu Y, Counter C, Wang XF. 
The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta. J Biol Chem
1999; 274(50):35381-7; PMID:10585406; https://doi.org/10.1074/jbc.274.50.35381</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.274.50.35381</ArticleId>
            <ArticleId IdType="pubmed">10585406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. 
Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate
1998; 37(1):19-29; PMID:9721065; https://doi.org/10.1002/(SICI)1097-0045(19980915)37:1%3c19::AID-PROS4%3e3.0.CO;2-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0045(19980915)37:1%3c19::AID-PROS4%3e3.0.CO;2-3</ArticleId>
            <ArticleId IdType="pubmed">9721065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, et al.. 
Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res
1999; 59(2):320-4; PMID:9927040</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9927040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grady WM, Willis JE, Trobridge P, Romero-Gallo J, Munoz N, Olechnowicz J, Ferguson K, Gautam S, Markowitz SD. 
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer
2006; 118(3):600-8; PMID:16108056</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16108056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al.. 
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science
1995; 268(5215):1336-8; PMID:7761852</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7761852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. 
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res
1995; 55(23):5548-50; PMID:7585632</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7585632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucke CD, Philpott A, Metcalfe JC, Thompson AM, Hughes-Davies L, Kemp PR, Hesketh R. 
Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer. Cancer Res
2001; 61(2):482-5; PMID:11212236</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11212236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Jonge RR, Garrigue-Antar L, Vellucci VF, Reiss M. 
Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol Res
1997; 9(2):89-98; PMID:9167190</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9167190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, Mogi A, Shitara Y, Takenoshita S. 
Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res
2000; 60(16):4507-12; PMID:10969799</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10969799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Carter D, Garrigue-Antar L, Reiss M. 
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res
1998; 58(21):4805-10; PMID:9809982</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9809982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. 
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res
1998; 58(23):5329-32; PMID:9850059</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9850059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. 
A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood
1999; 94(8):2854-61; PMID:10515889</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10515889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H, et al.. 
DPC4 gene in various tumor types. Cancer Res
1996; 56(11):2527-30; PMID:8653691</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8653691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, Seymour AB, Weinstein CL, Yeo CJ, Hruban RH, et al.. 
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res
1996; 56(3):490-4; PMID:8564959</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8564959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, et al.. 
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell
2007; 11(2):147-60; PMID:17292826</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17292826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. 
Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol
2008; 29(6):613-6; PMID:19115689</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19115689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer JR, Darjes H, Lahm H, Schindel M, Drings P, Krammer PH. 
Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer
1994; 30A(14):2125-9; PMID:7857713</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7857713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labidi SI, Menetrier-Caux C, Chabaud S, Chassagne C, Sebban C, Gargi T, Biron P, Blay JY, Ghesquières H. 
Serum cytokines in follicular lymphoma. Correlation of TGF-beta and VEGF with survival. Ann Hematol
2010; 89(1):25-33; PMID:19582455</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19582455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langenskiold M, Holmdahl L, Falk P, Angenete E, Ivarsson ML. 
Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol
2008; 97(5):409-15; PMID:18176914</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18176914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI. 
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol
2008; 26(9):1526-31; PMID:18349404</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18349404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, Matsuzawa Y. 
Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer
1994; 73(9):2275-9; PMID:7513247</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7513247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, Sarbia M. 
Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog
2006; 45(10):786-94; PMID:16921482</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16921482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen PJ, Ebner R, Lopez AR, Derynck R. 
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol
1994; 127(6 Pt 2):2021-36; PMID:7806579</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2120317</ArticleId>
            <ArticleId IdType="pubmed">7806579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oft M, Heider KH, Beug H. 
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol
1998; 8(23):1243-52; PMID:9822576</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9822576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. 
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev
1996; 10(19):2462-77; PMID:8843198</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8843198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. 
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J
1987; 6(7):1899-904; PMID:2820711</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC553574</ArticleId>
            <ArticleId IdType="pubmed">2820711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al.. 
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell
2008; 133(4):704-15; PMID:18485877</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2728032</ArticleId>
            <ArticleId IdType="pubmed">18485877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. 
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One
2008; 3(8):e2888; PMID:18682804</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2492808</ArticleId>
            <ArticleId IdType="pubmed">18682804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, Tsushima H, Matsuzawa Y. 
Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett
1995; 89(1):45-8; PMID:7882301</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7882301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madri JA, Pratt BM, Tucker AM. 
Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol
1988; 106(4):1375-84; PMID:3283153</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2115017</ArticleId>
            <ArticleId IdType="pubmed">3283153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. 
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem
1994; 269(9):6271-4; PMID:8119973</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8119973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, Ten Dijke P. 
Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene
2010; 29(9):1351-61; PMID:20010874</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20010874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin JH, Shim JW, Kim DS, Shim JY. 
TGF-beta effects on airway smooth muscle cell proliferation, VEGF release and signal transduction pathways. Respirology
2009; 14(3):347-53; PMID:19192227</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19192227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Lüttges J, Klöppel G, Graeven U, Eilert-Micus C, et al.. 
Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A
2000; 97(17):9624-9; PMID:10944227</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16915</ArticleId>
            <ArticleId IdType="pubmed">10944227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z. 
Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res
2007; 13(19):5692-702; PMID:17908958</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17908958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. 
Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J
2002; 21(7):1743-53; PMID:11927558</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC125949</ArticleId>
            <ArticleId IdType="pubmed">11927558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roelen BA, van Rooijen MA, Mummery CL. 
Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn
1997; 209(4):418-30; PMID:9264265</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9264265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie JC, Liggitt D, Rudensky AY. 
Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity
2006; 25(3):441-54; PMID:16973387</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16973387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al.. 
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature
1992; 359(6397):693-9; PMID:1436033</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3889166</ArticleId>
            <ArticleId IdType="pubmed">1436033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, Wahl SM. 
TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev
2003; 14(2):85-9; PMID:12651220</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12651220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE, Novault S, Escudier B, Vivier E, et al.. 
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med
2005; 202(8):1075-85; PMID:16230475</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2213209</ArticleId>
            <ArticleId IdType="pubmed">16230475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. 
Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol
2003; 170(7):3806-11; PMID:12646647</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12646647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET. 
Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res
2003; 63(8):1860-4; PMID:12702574</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12702574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. 
Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother
1988; 26(2):95-100; PMID:2452015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2452015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. 
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother
1993; 36(6):409-16; PMID:8500113</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8500113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker BF, Monia BP. 
Novel mechanisms for antisense-mediated regulation of gene expression. Biochim Biophys Acta
1999; 1489(1):3-18; PMID:10806993</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10806993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crooke ST.
Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta
1999; 1489(1):31-44; PMID:10806995</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10806995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P. 
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev
2006; 17(1-2):129-39</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16377233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ, Kielmanowicz M, Schneider A. 
Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci
2011; 102(6):1193-200; PMID:21366804</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21366804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlingensiepen R, Goldbrunner M, Szyrach MN, Stauder G, Jachimczak P, Bogdahn U, Schulmeyer F, Hau P, Schlingensiepen KH. 
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides
2005; 15(2):94-104; PMID:15989424</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15989424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine V, Parfenov V, et al.. 
Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol
2011; 13(1):132-42; PMID:20980335</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3018908</ArticleId>
            <ArticleId IdType="pubmed">20980335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, et al.. 
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides
2007; 17(2):201-12; PMID:17638524</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17638524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagaraj NS, Datta PK. 
Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs
2010; 19(1):77-91; PMID:20001556</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796203</ArticleId>
            <ArticleId IdType="pubmed">20001556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SG, Song JY. 
Therapeutic targeting of oncogenic transforming growth factor-beta1 signaling by antisense oligonucleotides in oral squamous cell carcinoma. Oncol Rep
2012; 28(2):539-44; PMID:22581233</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22581233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, et al.. 
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol
2006; 24(29):4721-30; PMID:16966690</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16966690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nemunaitis J, Nemunaitis M, Senzer N, Snitz P, Bedell C, Kumar P, Pappen B, Maples PB, Shawler D, Fakhrai H. 
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther
2009; 16(8):620-4; PMID:19287371</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19287371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, et al.. 
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer
2015; 51(16):2321-9; PMID:26283035</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26283035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, et al.. 
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer
2015; 51(16):2321-9; PMID:26283035</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26283035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, et al.. 
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res
2008; 68(10):3835-43; PMID:18483268</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2587151</ArticleId>
            <ArticleId IdType="pubmed">18483268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ. 
Effective chemoimmunotherapy with anti-TGFbeta antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One
2014; 9(1):e85398; PMID:24416401</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3887137</ArticleId>
            <ArticleId IdType="pubmed">24416401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. 
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest
2007; 117(5):1305-13; PMID:17415413</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838926</ArticleId>
            <ArticleId IdType="pubmed">17415413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, et al.. 
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer
2010; 9: 122; PMID:20504320</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2890606</ArticleId>
            <ArticleId IdType="pubmed">20504320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabe Y, Shi YX, Zeng Z, Jin L, Shikami M, Hatanaka Y, Miida T, Hsu FJ, Andreeff M, Konopleva M. 
TGF-beta-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment. PLoS One
2013; 8(6):e62785; PMID:23826077</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3695026</ArticleId>
            <ArticleId IdType="pubmed">23826077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S, Zuk A, Arbeeny C, Ledbetter S. 
Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One
2013; 8(1):e54499; PMID:23349909</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3547926</ArticleId>
            <ArticleId IdType="pubmed">23349909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulper P, Schulz-Schaeffer W, Dullin C, Hoffmann P, Harper J, Kurtzberg L, Lonning S, Kugler W, Lakomek M, Erdlenbruch B. 
Tumor localization of an anti-TGF-beta antibody and its effects on gliomas. Int J Oncol
2011; 38(1):51-9; PMID:21109925</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21109925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. 
Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. The Journal of clinical investigation
1993; 92(6):2569-76; PMID:7504687</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC288452</ArticleId>
            <ArticleId IdType="pubmed">7504687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. 
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One
2014; 9(3):e90353; PMID:24618589</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3949712</ArticleId>
            <ArticleId IdType="pubmed">24618589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, et al.. 
Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology
2013; 2(8):e26218; PMID:24179709</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3812201</ArticleId>
            <ArticleId IdType="pubmed">24179709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarper M, Cortes E, Lieberthal TJ, Del Rio Hernandez A. 
ATRA modulates mechanical activation of TGF-beta by pancreatic stellate cells. Sci Rep
2016; 6: 27639; PMID:27375161</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4931506</ArticleId>
            <ArticleId IdType="pubmed">27375161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng H, Wang J, Koteliansky VE, Gotwals PJ, Hauer-Jensen M. 
Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology
2000; 119(5):1286-96; PMID:11054386</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11054386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao W, Kobayashi M, Ding W, Yuan L, Seth P, Cornain S, Wang J, Okada F, Hosokawa M. 
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother
2002; 51(7):381-8; PMID:; PMID:12192538</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12192538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M. 
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res
2001; 7(9):2931-40; PMID:11555612</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11555612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, et al.. 
Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest
2002; 109(12):1551-9; PMID:12070302</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151012</ArticleId>
            <ArticleId IdType="pubmed">12070302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM. 
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res
2004; 10(17):5907-18; PMID:15355924</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15355924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Berndt BE, Chen JJ, Kao JY. 
Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol
2008; 181(5):3690-7; PMID:18714045</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18714045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Gerseny H, Zhang Z, Chen YJ, Berg A, Zhang Z, Stock S, Seth P. 
Oncolytic adenovirus expressing soluble TGFbeta receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther
2011; 19(9):1609-18; PMID:21712815</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3182349</ArticleId>
            <ArticleId IdType="pubmed">21712815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen YJ, Zhang Z, Du H, Brendler CB, Xiao X, et al.. 
Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther
2012; 23(8):871-82; PMID:22551458</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3413899</ArticleId>
            <ArticleId IdType="pubmed">22551458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Hu Z, Gupta J, Krimmel JD, Gerseny HM, Berg AF, Robbins JS, Du H, Prabhakar B, Seth P. 
Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther
2012; 19(9):630-6; PMID:22744210</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3424293</ArticleId>
            <ArticleId IdType="pubmed">22744210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 
The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest
2007; 117(1):206-17; PMID:17160136</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1679965</ArticleId>
            <ArticleId IdType="pubmed">17160136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JD, Hempel N, Lee NY, Blobe GC. 
The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis
2010; 31(2):175-83; PMID:19955393</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2812570</ArticleId>
            <ArticleId IdType="pubmed">19955393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naumann U, Maass P, Gleske AK, Aulwurm S, Weller M, Eisele G. 
Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. Int J Oncol
2008; 33(4):759-65; PMID:18813789</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18813789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. 
TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis
2008; 29(3):528-35; PMID:18174241</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18174241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ. 
Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res
2002; 62(16):4690-5; PMID:12183427</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12183427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L. 
A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res
1999; 59(19):5041-6; PMID:10519421</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10519421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, et al.. 
Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol
2002; 62(1):58-64; PMID:12065755</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12065755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y, Jiang F, Zheng X, Katakowski M, Buller B, To SS, Chopp M. 
TGF-beta1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncol Rep
2011; 25(5):1329-35; PMID:21359495</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3070292</ArticleId>
            <ArticleId IdType="pubmed">21359495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi K, Abe M, Hiasa M, Oda A, Amou H, Kido S, Harada T, Tanaka O, Miki H, Nakamura S, et al.. 
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One
2010; 5(3):e9870; PMID:20360846</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2845613</ArticleId>
            <ArticleId IdType="pubmed">20360846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miles FL, Tung NS, Aguiar AA, Kurtoglu S, Sikes RA. 
Increased TGF-beta1-mediated suppression of growth and motility in castrate-resistant prostate cancer cells is consistent with Smad2/3 signaling. Prostate
2012; 72(12):1339-50; PMID:22228025</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22228025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, Kubo N, Ohira M, Hirakawa K. 
Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep
2010; 24(6):1637-43; PMID:21042762</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21042762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, et al.. 
Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci
2007; 98(1):127-33; PMID:17129361</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17129361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K. 
Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer
2010; 102(5):844-51; PMID:20145621</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2833252</ArticleId>
            <ArticleId IdType="pubmed">20145621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et al.. 
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res
2004; 64(21):7954-61; PMID:15520202</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, et al.. 
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res
2004; 10(22):7540-6; PMID:15569984</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15569984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, et al.. 
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood
2008; 112(8):3434-43; PMID:18474728</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2569182</ArticleId>
            <ArticleId IdType="pubmed">18474728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al.. 
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res
2006; 12(14 Pt 1):4315-30; PMID:16857807</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16857807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, et al.. 
Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res
2007; 27(6B):4149-57; PMID:18229422</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18229422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, et al.. 
Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Molecular Pharmacol
2007; 72(1):152-61; PMID:17400764</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17400764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. 
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res
2011; 71(1):175-84; PMID:21084275</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3225124</ArticleId>
            <ArticleId IdType="pubmed">21084275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Q, Zhang XM, Duan KZ, Gu XY, Han M, Liu BL, Zhao ZQ, Zhang YQ. 
Peripheral TGF-beta1 signaling is a critical event in bone cancer-induced hyperalgesia in rodents. J Neurosci
2013; 33(49):19099-111; PMID:24305807</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6618781</ArticleId>
            <ArticleId IdType="pubmed">24305807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ. 
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther
2008; 7(4):829-40; PMID:18413796</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3088432</ArticleId>
            <ArticleId IdType="pubmed">18413796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK. 
Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology
2010; 138(3):969-80
e1-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831103</ArticleId>
            <ArticleId IdType="pubmed">19909744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B, Halder SK, Zhang S, Datta PK. 
Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett
2009; 277(1):114-20; PMID:19147275</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2776056</ArticleId>
            <ArticleId IdType="pubmed">19147275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzocca A, Fransvea E, Lavezzari G, Antonaci S, Giannelli G. 
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology
2009; 50(4):1140-51; PMID:19711426</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19711426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fransvea E, Mazzocca A, Santamato A, Azzariti A, Antonaci S, Giannelli G. 
Kinase activation profile associated with TGF-beta-dependent migration of HCC cells: a preclinical study. Cancer Chemother Pharmacol
2011; 68(1):79-86; PMID:20844878</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20844878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dituri F, Mazzocca A, Fernando J, Papappicco P, Fabregat  I, De Santis F, Paradiso A, Sabbà C, Giannelli G. 
Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II. PLoS One
2013; 8(6):e67109; PMID:23826206</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3694933</ArticleId>
            <ArticleId IdType="pubmed">23826206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M, Huber PE. 
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-beta receptor I kinase inhibitor LY2109761. Neoplasia
2011; 13(6):537-49; PMID:21677877</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3114247</ArticleId>
            <ArticleId IdType="pubmed">21677877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, et al.. 
Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res
2011; 71(23):7155-67; PMID:22006998</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22006998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, et al.. 
TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res
2011; 17(21):6754-65; PMID:22028490</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3724539</ArticleId>
            <ArticleId IdType="pubmed">22028490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. 
Effect of transforming growth factor beta (TGF-beta) receptor I kinase inhibitor on prostate cancer bone growth. Bone
2012; 50(3):695-703; PMID:22173053</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3278589</ArticleId>
            <ArticleId IdType="pubmed">22173053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connolly EC, Freimuth J, Akhurst RJ. 
Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci
2012; 8(7):964-78; PMID:22811618</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3399319</ArticleId>
            <ArticleId IdType="pubmed">22811618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maier A, Peille AL, Vuaroqueaux V, Lahn M. 
Anti-tumor activity of the TGF-beta receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cell Oncol (Dordr)
2015; 38(2):131-44; PMID:25573078</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4412926</ArticleId>
            <ArticleId IdType="pubmed">25573078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee GT, Hong JH, Mueller TJ, Watson JA, Kwak C, Sheen YY, Kim DK, Kim SJ, Kim IY. 
Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/activin receptor-like kinase-5, on prostate cancer cells. J Urol
2008; 180(6):2660-7; PMID:18951571</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18951571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY. 
An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett
2014; 351(1):72-80; PMID:24887560</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24887560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IF. 
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer
2008; 44(1):142-50; PMID:18039567</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18039567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al.. 
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther
2015; 9: 4479-99; PMID:26309397</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4539082</ArticleId>
            <ArticleId IdType="pubmed">26309397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM. 
Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol
2014; 77(5):796-807; PMID:24868575</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4004400</ArticleId>
            <ArticleId IdType="pubmed">24868575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara Y, Nokihara H, Yamada Y, Yamamoto N, Sunami K, Utsumi H, Asou H, TakahashI O, Ogasawara K, Gueorguieva I, et al.. 
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol
2015; 76(6):1143-52; PMID:26526984</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26526984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, et al.. 
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs
2015; 33(2):357-70; PMID:25529192</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387272</ArticleId>
            <ArticleId IdType="pubmed">25529192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Q, Lim SK, Zhao B, Hoffmann FM. 
Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene
2005; 24(24):3864-74; PMID:15750622</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15750622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao BM, Hoffmann FM. 
Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell
2006; 17(9):3819-31; PMID:16775010</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1556379</ArticleId>
            <ArticleId IdType="pubmed">16775010</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
